How about Some Biotech Stocks for Growth Investment

Experts believe the biotech industry has opened up to some great opportunities for growth investors. Here are two examples.

Trading stocks online is a great way to be initiated into the world of stock trading. The major aim of stock trading is to be able to able to make profitable trades. Traders always search for stocks that have great growth potential. Growth leads to higher stock value. For online traders, the right stock trading software can give them a clear idea of the market and stock performance so they can have some idea as to whether the stocks they buy will end up becoming profitable.

For growth investors there are two great stocks out there in the biotech sector, according to experts:

Omeros

biotechLet’s analyze Omeros Corporation ($OMER). The company’s Omidria pupil-dilating solution is selling well, with sales jumping a whopping 212% higher than the levels in 2015. And more growth is expected. The solution helps in lens replacement and cataract removal surgeries. These procedures are performed frequently globally, and in the US alone they are performed around 4 million times annually. Omeros earned $41.4 million in product sales in 2016. Omidria is priced at around $465 per vial.

Ionis

biotechIonis Pharmaceuticals ($IONS) is a stock that may not yet be enjoying recurring profitability. But it has significant potential, which is why it must be looked at by growth seeking investors. What gives Ionis the edge is its antisense drug development platform that enables it to predict the performance of its newly developed drugs in the treatment of specific ailments. This helps it to release five new drugs for clinical testing each year. This indicates that it can release drugs into the market at a faster rate.

Currently, Ionis has 24 drugs in the clinical study stage. Many of these drugs are developed with its licensing partners. The company’s research is fueled by its milestone payment revenue which it manages to accrue almost regularly thanks to its ability to partner up.

The Spinraza drug, for which Ionis partnered with Biogen, has the potential to be the first major profit-generating drug for the company. The spinal muscular atrophy drug costs as high as $750,000 in year one and $375,000 in subsequent years.

There are sufficient indications of the growth potential of these stocks. The biotech industry is indeed opening up to some great possibilities. As always, investors can trade all biotech stocks like $IONS and $OMER commission free both long and short with TradeZero.
TradeZero on FacebookTradeZero on Twitter
TradeZero is an online broker dealer that offers commission free trading of the US equity markets, US equity and index options trading, along with a 14,000+ symbol short list of the US markets. Its clients receive up to 6 to 1 intraday leverage and the ability to trade the US markets without any pattern day trading rules. TradeZero clients have access to a variety of cutting edge trading platforms which include real-time streaming market data.

TradeZero

TradeZero is an online broker dealer that offers commission free trading of the US equity markets, US equity and index options trading, along with a 14,000+ symbol short list of the US markets. Its clients receive up to 6 to 1 intraday leverage and the ability to trade the US markets without any pattern day trading rules. TradeZero clients have access to a variety of cutting edge trading platforms which include real-time streaming market data.

    One thought on “How about Some Biotech Stocks for Growth Investment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Translate »